Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 12,241 matching trials from the live ClinicalTrials.gov search.
Conditions
Peripheral Vascular Disease, Cardiovascular Disease
Interventions
Vessel Closure (StarClose™)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
11
States / cities
La Jolla, California • Atlanta, Georgia • Peoria, Illinois + 8 more
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Melphalan/HDS, Sorafenib
Device · Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
entinostat
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Hypertension
Interventions
CIN-107, Matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Multiple Myeloma, Amyloidosis
Interventions
DaraVRD/DaraVCD
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Dry Eye Syndrome (DES), Meibomian Gland Dysfunction (Disorder)
Interventions
Manual expression of meibomian glands after thermal eyelid therapy
Device
Lead sponsor
Cleveland Eye Clinic
Other
Eligibility
50 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Largo, Florida • Brecksville, Ohio
Conditions
Multiple Myeloma
Interventions
Azacitidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo
Behavioral · Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Conditions
VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
Interventions
Belzutifan
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Bethesda, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Conditions
Diabetic Foot
Interventions
SkinTE, Control
Biological · Other
Lead sponsor
PolarityTE
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
23
States / cities
Mesa, Arizona • Castro Valley, California • Fresno, California + 19 more
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more
Conditions
Age Related Macular Degeneration
Interventions
aflibercept 2.0 mg
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Multifaceted cognitive training
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Multiple Sclerosis
Interventions
Electrostimulation suit
Device
Lead sponsor
Otto Bock Healthcare Products GmbH
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lymphoma, Non-Hodgkin
Interventions
SAR3419
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Multiple Myeloma
Interventions
Cilta-cel OOS Therapy
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
U.S. locations
137
States / cities
Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Pulmonary Sarcoidosis
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Albany, New York • Cleveland, Ohio
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Beverly Hills, California • Plantation, Florida + 5 more
Completed Phase 2 Interventional Results available

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380
Conditions
EoE, Eosinophilic Esophagitis
Interventions
Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
Conditions
Relapsing Multiple Sclerosis
Interventions
Blood sampling
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Conditions
Multiple Myeloma
Interventions
Melphalan, Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
60 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers

Reducing HIV Risk With High Risk HIV Negative Black MSM-Passport to Wellness

NCT02932384
Conditions
HIV, Men
Interventions
Intervention-Passport and Peer Mentor, Control-Passport Only
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older · Male only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Los Angeles, California